George Budwell

George Budwell

TMFGBudwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles









Is Gilead Sciences a Bad News Buy?

Gilead's fourth-quarter numbers failed to hit the mark, but the company firmly believes that better days are directly ahead.






3 Top Value Stocks to Buy Right Now

If you're looking for a value stock to add to your portfolio this year, these three names should be on your radar.